AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.
The stock's fall snapped a two-day winning streak.
According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...
If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...
But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...
With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...
The Forced Swim Test developed in 1977, models depression using mice or rats to screen for antidepressant medications. It has ...
The next frame shows the Ubrelvy logo in the backstage hallway along with a blue lit path. Frames six to seven then show Serena Williams walking down the blue lit path, no longer exhibiting migraine ...
Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...
On CNBC's “Halftime Report Final Trades,” Stephen L. Weiss of Short Hills Capital Partners recommended buying TransDigm Group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback